Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
INKT Stock Chart & Stats
$12.75
-$0.11(-11.96%)
At close: 4:00 PM EST
$12.75
-$0.11(-11.96%)
Day’s Range― - ―
52-Week Range$4.56 - $76.00
Previous CloseN/A
Volume98.55K
Average Volume (3M)39.56K
Market Cap
$57.94M
Enterprise Value$33.24M
Total Cash (Recent Filing)$14.28B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Mar 24, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding4,522,927
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.33
Price to Sales (P/S)0.00
P/FCF Ratio-2.73
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda-3.67
Forecast
1Y Price Target
$39.00Price Target Upside205.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMiNK announced new Phase 2 trials in planning for agenT-797 in GvHD, severe pulmonary disease, and solid tumors.
Funding And InitiativesThe trial of agenT-797 for the prophylactic treatment of graft versus host disease (GvHD) will be externally funded and is expected to initiate soon.
Therapeutic ImpactThe company aims for a 50% reduction in GvHD cases, highlighting a significant potential impact on patient outcomes.
Bears Say
Clinical Trial LimitationsWhile it was encouraging to see a significant mOS benefit we note the combo cohort was only 6 patients; therefore, a larger Phase 2 trial is necessary to understand iNKT's potential as a first-in-class therapy for r/r solid tumors.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $4.56 and its highest was $76.00 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $57.94M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 128 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Nov 14, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.855 by $0.205.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.89.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 4,522,927 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.855. Following the earnings report the stock price went down -3.555%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
MiNK Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (205.88% Upside)
$39.00 (205.88% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-75.93%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics (INKT) is a biotechnology company focused on the development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-related diseases. Leveraging its proprietary technology platform, MiNK aims to address unmet medical needs by harnessing the unique properties of iNKT cells, which can modulate the immune system and target tumor cells. The company's core products are based on its innovative cell therapy pipeline designed to provide effective and scalable treatment options.
INKT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for MiNK Therapeutics was predominantly positive, highlighting significant clinical trial successes, strategic partnerships, and advancements in manufacturing capabilities. While there was an increase in net loss, the company's financial strategy and strong leadership suggest a positive outlook for future growth.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$39.00
▲(205.88% Upside)
Technical Analysis
Ownership Overview
4.30% Insiders
0.74% Mutual Funds
0.38% Other Institutional Investors
94.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---